A public company based in China has its core businesses in-vitro diagnostics and radiation therapy. The corporate fund of this company is looking to work with early-stage medical device companies using a variety of structures, including equity investments and M&A. The firm is looking to engage in Seed to Series B/C and the average check size is usually less than 10M USD. The firm is open to opportunities worldwide and prefers companies with some sort of China angles. The firm is looking to make 3-4 new investments within the next 12 months. 
 
While the firm’s core business is in IVD and radiation therapy, the firm is interested in medical devices of all classes. 
 
The firm does not have any specific requirements for the company’s management team, but they do prefer companies with a China angle. The firm is open to both leading and co-investing and is likely to take a board seat when leading. The firm looks to be an active investor and strategically collaborate with their portfolio companies to create synergies. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A joint venture founded between a family office and a holding company is interested in Series A and B medical device companies in the U.S. and Western Europe that are near FDA approval. The firm is also open to Korean and Japanese companies. Typical check sizes range between USD $500k-1.5M, preferring to lead transactions. The firm will also co-invest with the family office’s other investment vehicles to secure right in late-stage revenue-generating companies with a clear path to exit within an 18-24 month time frame. 
 
The firm is interested open to all classes of medical devices, but mainly focuses on human implants. Their core focus is in the neuromuscular space, including orthopedics and spine implants. They are also interested in cardiology, vascular devices, surgical devices, oncology biopharma. Currently, they are looking to expand their core area and look at more cardiovascular, arterial and peripheral devices. Companies should be near FDA approval with proven technology. 
 
The firm requires to take a board seat, observer at minimum. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm headquartered in Western Europe is led by a small, academically focused team located throughout the globe in London, the USA, and Israel. The firm makes, on average, 4-6 investments per year with a total of 20 initial ticket investments via their current fund. The firm invests in pre-clinical companies in early stages, with a sweet spot for Seed and Series A rounds. The firm is open to making investments via any investment vehicle, typically in the form of equity, safe or convertible notes. The firm will invest up to $5-6M. The firm invests globally, with a large number of investments in North America. 
 
The firm invests solely in therapeutics. The firm is focused on “advanced therapeutics”, encompassing anything that is highly targeted such as gene therapy, cell therapy, siRNA, genetic medicine and computational biology. The firm is indication agnostic, with a large interest, however, in oncology. 
 
The firm will co-lead or syndicate rounds, with a preference to co-lead. The firm has no specific team requirements. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm actively invests in pre-seed and seed stage companies. Typical initial size of investment ranges from $1-1.5M. The firm focuses on the following areas: digital economy, climate & environment, health & well-being. The firm is strongly interested in companies based in North America and Latin America. 
 
Historically, the firm has been agnostic towards technology area and indications. That said, the firm is currently interested in exploring opportunities in new modalities and biologics, and expanding their interests in peptide-based therapies and induced proximity therapeutics (i.e. molecular glues, PROTACs). The firm invests mainly in pre-clinical and early clinical therapeutics. The firm actively invests in therapeutics, diagnostics, and life science tools. 
 
The firm seeks to work with exceptional entrepreneurs who are passionate about their work, and is open to working with first-time entrepreneurs. The firm’s investment process starts from an initial meeting and evaluating the opportunity, a decision analysis including the addressed market, life stages assessment, and a final assessment, and if choosing to move forward, proceeding with legal due diligence and signing/execution. To date, the firm has led about 50% of their deals, and following in the other half. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm of a family-owned service provider seeks investments in Seed to Series A/B, with an initial check ranging between 3-7 million Euros. Follow-on investments are possible, and the firm may invest up to 15 million Euros throughout the life cycle. The firm is open to both leading and co-investing. The firm focuses on opportunities in Europe, UK and US. 
 
The firm is interested in early-stage therapeutic technologies. The firm is agnostic regarding modalities and indications, and is open to exploring different types of therapeutic assets. Additionally, the firm has invested in orphan drugs. While there is no strict mandate for the development phases of assets, having at least in-vivo data would generally be preferred. 
 
There are no specific requirements for companies’ management team. 
 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture arm of a global pharmaceutical company with a market cap exceeding $11 billion, is actively investing in the early-stage healthcare sector. The firm focuses on pre-seed/seed-stage opportunities, with the initial investment range spanning 0.5-2 million. The firm is interested in opportunities globally with a focus in the US. The firm is open to both leading and co-investing and will consider board seats when leading the round. While the firm is mostly finance driven, the firm is able to bring in the strategic perspective if deemed necessary. 
 
The firm seeks companies with innovative sciences addressing highly unmet needs. The firm is focused on therapeutic, including cell and gene therapy, small molecules, radiopharmaceuticals, CRISPR, and data-driven technologies such as AI-driven drug discovery. The firm is interested in oncology, neurology, and rare diseases. Less invasive diagnostic technologies are also within the scope. The firm mostly works with companies in the preclinical to phase I stages. 
 
The firm focuses on finding promising science backed by strong IP. As an active investor, the firm supports portfolio companies through its extensive network and resources.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm headquartered in Western Europe is focused on enabling technology within life sciences and healthcare. firm will make initial investments ranging from at a minimum of 1M euro, and will make follow-on investments in total adding up to 5M-7M euro. The firm will invest in Seed-Series B companies. The firm will be launching their new fund in 2025. The firm aims to be a meaningful investor, looking to lead deals, but will also co-lead and can syndicate in certain cases. The firm will generally invest within Western Europe. 
 
The firm will invest in diagnostics, medical devices, and digital health. The firm is not open to investing in therapeutics. The firm is not interested in invasive devices and will not invest in Class 3 and some Class 2 devices. The firm will look at companies with IND approval and in early-clinical stages. 
 
The firm does not have any specific team requirements. The firm considers themselves active, hands-on investors and will typically require a board seat. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.